MTX-463

Phase 2Biologic

MMediar Therapeutics

MTX-463 is one of 71 biologic programs targeting Idiopathic Pulmonary Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Pulmonary FibrosisActive, not recruiting

AdultRecruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

AdultPhase 1

Recruiting

Competition

Competitive Landscape

120 competitors in Adult

#DrugCompanyPhaseTrials

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 2

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 2

1 4

Rifampicin

Boehringer Ingelheim

Phase 3

3 5

Opzelura

DDizal Pharmaceuticals

Phase 2

1 6

Skyclarys

Biogen

Phase 1

3 7

Sunlenca

Gilead

Phase 1

1 8

Briviact

UCB

Phase 1

1 9

NM8074

NNovelMed Therapeutics

Phase 2

2 10

Lupron

Sun Pharmaceutical Industries, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Idiopathic Pulmonary Fibrosis

NCT06967805

Clinical

Trials by Indication[1]

Trial1 trial

A First-in-Human Safety Trial of MTX-463

Completed·MMediar Therapeutics·Phase 1·NCT06401213·56 enrolled

Adult1 trial

Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males

Recruiting·MMediar Therapeutics·Phase 1·NCT07450521·8 enrolled

Idiopathic Pulmonary Fibrosis1 trial

A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Active, not recruiting·MMediar Therapeutics·Phase 2·NCT06967805·168 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for MTX-463. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MTX-463 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MTX-463. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mediar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMediar Therapeutics

MTX-463

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Trial1 trial

Adult1 trial

Idiopathic Pulmonary Fibrosis1 trial

References

Drug Info

Quick Facts

Related News